Oculis Holding AG
OCS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001953530
No open-market purchases or sales by Oculis Holding AG insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $322.0M in total; no superinvestor holds it.
Other share classesOCSAW
13F holders, Q1 2025
Institutional positions in Oculis Holding AG as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- +8 vs. Q4 2024
- Shares held
- 4.98M
- +1.48M (+42.5%) vs. Q4 2024
- Total value
- $94.7M
- +$35.4M (+59.6%) vs. Q4 2024
- New holders
- 10
- 8 more added
- Sold out
- 2
- 1 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting OCS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 59 | $322.0M |
| Q1 2026 | 57 | $534.7M |
| Q4 2025 | 41 | $363.8M |
| Q3 2025 | 20 | $191.7M |
| Q2 2025 | 23 | $99.1M |
| Q1 2025 | 20 | $94.7M |
| Q4 2024 | 12 | $59.4M |
| Q3 2024 | 10 | $36.9M |
| Q2 2024 | 11 | $39.8M |
| Q1 2024 | 9 | $40.9M |
| Q4 2023 | 7 | $44.3M |
| Q3 2023 | 9 | $32.1M |
| Q2 2023 | 9 | $38.5M |
| Q1 2023 | 7 | $23.2M |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Oculis Holding AG; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| DuPont Capital Management Corp | 4 | $76 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 4 | $76 | 0.00% | +4 | New |
| Tower Research Capital LLC (TRC) | 26 | $495 | 0.00% | +26 | New |
| Wolverine Asset Management LLC | 399 | $7.59K | 0.00% | +399 | New |
| JPMorgan Chase & Co | 600 | $11.4K | 0.00% | +600 | New |
| Morgan Stanley | 5,116 | $97.4K | 0.00% | +5,116 | New |
| State Street Corp | 11,959 | $227.6K | 0.00% | +11,959 | New |
| Kestra Private Wealth Services, LLC | 12,322 | $234.5K | 0.00% | +12,322 | New |
| Bellevue Group AG | 14,100 | $268.3K | 0.01% | +4,100+41.0% | Added |
| Geode Capital Management, LLC | 23,052 | $438.7K | 0.00% | +6,308+37.7% | Added |
| Northern Trust Corp | 23,832 | $453.5K | 0.00% | +10,267+75.7% | Added |
| Bank of America Corp | 39,634 | $754.2K | 0.00% | +10,654+36.8% | Added |
| Compagnie Lombard Odier SCmA | 87,000 | $1.66M | 0.02% | −8,750−9.1% | Reduced |
| UBS Group AG | 112,965 | $2.15M | 0.00% | +4,123+3.8% | Added |
| Acuta Capital Partners, LLC | 125,000 | $2.38M | 2.76% | +125,000 | New |
| Alyeska Investment Group, L.P. | 131,332 | $2.50M | 0.01% | +131,332 | New |
| Sr One Capital Management, LP | 322,500 | $6.14M | 1.58% | +322,500 | New |
| Nan Fung Group Holdings Ltd | 514,702 | $9.79M | 7.99% | +78,324+17.9% | Added |
| Standard Life Aberdeen plc | 1,253,119 | $23.8M | 0.05% | +243,695+24.1% | Added |
| Pivotal bioVenture Partners Investment Advisor LLC | 2,300,774 | $43.8M | 35.43% | +563,078+32.4% | Added |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −22,911−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −13,249−100.0% | Sold out |